Evolus, Inc. (NASDAQ:EOLS) Insider David Moatazedi Sells 6,251 Shares

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the sale, the insider now owns 508,619 shares in the company, valued at $6,306,875.60. The trade was a 1.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Evolus Stock Down 1.6 %

Shares of EOLS stock opened at $12.05 on Monday. Evolus, Inc. has a 52-week low of $9.25 and a 52-week high of $17.82. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The stock has a market cap of $766.22 million, a price-to-earnings ratio of -13.24 and a beta of 1.28. The firm’s 50-day moving average is $13.66 and its 200-day moving average is $13.78.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on EOLS. Barclays raised their price objective on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Evolus in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research note on Wednesday, March 5th.

Institutional Trading of Evolus

Several institutional investors and hedge funds have recently bought and sold shares of the business. Tang Capital Management LLC increased its holdings in shares of Evolus by 3.1% during the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company’s stock worth $55,171,000 after acquiring an additional 150,000 shares during the last quarter. Nantahala Capital Management LLC increased its holdings in shares of Evolus by 10.8% in the fourth quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company’s stock valued at $34,557,000 after purchasing an additional 305,300 shares during the last quarter. Caligan Partners LP raised its position in shares of Evolus by 22.7% in the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock valued at $29,724,000 after purchasing an additional 498,900 shares during the period. Millennium Management LLC lifted its stake in shares of Evolus by 29.1% during the 4th quarter. Millennium Management LLC now owns 1,368,423 shares of the company’s stock worth $15,107,000 after buying an additional 308,753 shares during the last quarter. Finally, Boothbay Fund Management LLC boosted its holdings in shares of Evolus by 30.9% during the 4th quarter. Boothbay Fund Management LLC now owns 1,287,767 shares of the company’s stock worth $14,217,000 after buying an additional 304,065 shares during the period. Institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.